ArticleMolecular therapy. Methods & clinical development2015
Generation of a stable packaging cell line producing high-titer PPT-deleted integration-deficient lentiviral vectors.
Article in Molecular therapy. Methods & clinical development, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 15 citations in OpenAlex.
- Application Advances of Lentiviral Vectors: From Gene Therapy to Vaccine Development.Molecular biotechnology · 2026Review
- All-in-one IQ toggle switches with high versatilities for fine-tuning of transgene expression in mammalian cells and tissues.Molecular therapy. Methods & clinical development · 2024Article
- The transformative potential of HSC gene therapy as a genetic medicine.Gene therapy · 2023Review
- Production of Lentiviral Vectors Using a HEK-293 Producer Cell Line and Advanced Perfusion Processing.Frontiers in bioengineering and biotechnology · 2022Article
- Novel immortalized human vocal fold epithelial cell line: In vitro tool for mucosal biology.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2021Article
- Review
- Superior lentiviral vectors designed for BSL-0 environment abolish vector mobilization.Gene therapy · 2018Article
- Targeted in vivo knock-in of human alpha-1-antitrypsin cDNA using adenoviral delivery of CRISPR/Cas9.Gene therapy · 2018Article
- In Vivo Excision of HIV-1 Provirus by saCas9 and Multiplex Single-Guide RNAs in Animal Models.Molecular therapy : the journal of the American Society of Gene Therapy · 2017Article
- Functional screening of guide RNAs targeting the regulatory and structural HIV-1 viral genome for a cure of AIDS.AIDS (London, England) · 2016Article
- Progress and challenges in viral vector manufacturing.Human molecular genetics · 2016Review
- Experimental methods to preserve male fertility and treat male factor infertility.Fertility and sterility · 2016Review
- Production of lentiviral vectors.Molecular therapy. Methods & clinical development · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The risk of insertional mutagenesis inherent to all integrating exogenous expression cassettes was the impetus for the development of various integration-defective lentiviral vector (IDLV) systems. These systems were successfully employed in a plethora of preclinical applications, underscoring their clinical potential. However, current production of IDLVs by transient plasmid transfection is not optimal for large-scale production of clinical grade vectors. Here, we describe the development of the first tetracycline-inducible stable IDLV packaging cell line comprising the D64E integrase mutant and the VSV-G envelope protein. A conditional self-inactivating (cSIN) vector and a novel polypurine tract (PPT)-deleted vector were incorporated into the newly developed stable packaging cell line by transduction and stable transfection, respectively. High-titer (~10(7) infectious units (IU)/ml) cSIN vectors were routinely generated. Furthermore, screening of single-cell clones stably transfected with PPT-deleted vector DNA resulted in the identification of highly efficient producer cell lines generating IDLV titers higher than 10(8) IU/mL, which upon concentration increased to 10(10) IU/ml. IDLVs generated by stable producer lines efficiently transduce CNS tissues of rodents. Overall, the availability of high-titer IDLV lentivirus packaging cell line described here will significantly facilitate IDLV-based basic science research, as well as preclinical and clinical applications.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.